
|Videos|March 15, 2017
High Cost Impacts PCSK9 Inhibitor Access
Author(s)Lauren Santye, Assistant Editor
Mark Tesell, PharmD, BCPS, discusses how the high cost of PCSK9 inhibitors effected uptake of the cholesterol-lowering drug.
Advertisement
Mark Tesell, PharmD, BCPS, discusses how the high cost of PCSK9 inhibitors effected uptake of the cholesterol-lowering drug.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pennsylvania Confirms First Measles Deaths in 35 Years as US Case Count Tops 2900
2
New Lipid Drugs and What Pharmacists Need to Know
3
Beyond GLP-1: Amylin, Glucagon Enter Obesity Care
4
FDA Approves Ustekinumab Injection for Pediatric Ulcerative Colitis, Expanding IBD Options for Children
5

































































































